TY - JOUR T1 - COVID-19 infection and hospitalization according to the burden of chronic noncommunicable diseases in Brazil JF - medRxiv DO - 10.1101/2021.05.03.21256532 SP - 2021.05.03.21256532 AU - Fabiana R. Ferraz AU - Wolney L. Conde AU - Isabela Venancio AU - Larrisa Lopes AU - Catarina M. Azeredo Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/05/2021.05.03.21256532.abstract N2 - Chronic diseases, worse socioeconomic conditions and old age can increase infection and hospitalization rate due to Coronavirus disease (COVID-19). We assessed the association between the burden of NCDs and the occurrence of infections and hospitalizations of COVID-19 in Brazil in a large COVID-19 national survey data. We analyzed only data collected between July and November 2020 (n = 1,071,782). The frequencies of positive COVID-19 diagnosis and NCD burden were estimated according to age, sex, socioeconomic strata and skin color categories. We estimated hazard ratios and 95% confidence intervals using Cox regression models. There is a non-linear dose-response inverse association between per capita income and the rates of infection and hospitalization due to COVID-19. The presence of NCDs was associated with a higher incidence of COVID-19 infection (HR1NCD = 1.34; 95% CI: 1.26; 1.43; HR2 or more NCD= 1.54 95% CI: 1.39; 1.71) and incidence of hospitalization (HR1NCD = 3.08 95% CI: 2.26; 4.19; HR 2or more NCD= 6.81 95% CI: 4.88; 9.49).The difference between the risks of infection or hospitalization of COVID-19 attributable to the burden of NCDs is non-linearly associated with the income.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe had no funding for that analysis. All authors had full access to the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in the paper are public and avaiable to download at:https://www.ibge.gov.br/en/statistics/social/labor/27975-weekly-release-pnadcovid1.html?=&t=o-que-eAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this work can be obtained free at the Data service (https://www.ibge.gov.br/en/statistics/experimental-investigations/experimental-statistics/27975-weekly-release-pnadcovid1.html?=&t=microdados) Further information regarding the sample design and data collection methods can be found on the survey website (https://www.ibge.gov.br/en/statistics/experimental-investigations/experimental-statistics/27975-weekly-release-pnadcovid1.html?=&t=notas-tecnicas). ER -